Effect of His-Ventricular (HV) Interval Optimisation in Cardiac Resynchronisation Therapy

Not Applicable

Completed

• Conditions: Heart Failure
• Interventions: Other: His-Ventricular (HV) optimisation

• Registration Number: NCT02748876
• Lead Sponsor: Hull University Teaching Hospitals NHS Trust

Brief Summary

Cardiac resynchronisation therapy (CRT) is a specialised type of pacemaker used in patients with severe heart failure to improve symptoms and survival. Approximately one third of patients treated with CRT do not notice significant improvement in their symptoms and this may be due to inadequate co-ordination between the upper and lower chambers of the heart (atrioventricular dyssynchrony).

The investigators propose a new method to achieve atrioventricular synchrony in CRT based on measurements of electrical conduction from within the heart. Patients referred for CRT implantation at Castle Hill Hospital are eligible to participate. During CRT implantation, additional measurements, will be recorded from within the heart. After implantation, device settings will be adjusted to either standard or electrophysiologically-optimised settings with cross-over at 4 months.

The investigators hypothesis is that patients with optimised settings will derive additional benefit compared to patients with standard pacemaker-determined settings.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-04-20
• Study First Submitted QC: 2016-04-21
• Study First Posted: 2016-04-22
• Study Start: 2016-09-29
• Primary Completion: 2017-04-28
• Study Completion: 2018-03-15
• Status Verified: 2019-07
• Last Update Submitted: 2019-07-15
• Last Update Posted: 2019-07-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

• Clinical diagnosis of heart failure
• Referred for cardiac resynchronisation therapy (CRT) with or without defibrillator
• In sinus rhythm
• Patients must have a telephone
• Ability to give informed consent
• Ability to complete the study

Exclusion Criteria

• Severe valve disease or previous valve replacement
• Previous atrial flutter ablation
• Chronic kidney disease Stage 3 or above
• Recent myocardial infarction
• Ongoing cardiac ischaemia
• Infiltrative cardiomyopathy
• Wolff-Parkinson White syndrome
• Presence of second or third degree heart block
• <90% biventricular pacing at 3 months
• Hypertrophic cardiomyopathy
• Pregnancy or breastfeeding
• On treatment for hypothyroidism or hyperthyroidism

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
His-Ventricular (HV)-optimised	His-Ventricular (HV) optimisation	His-Ventricular (HV) optimised atrioventricular delay

Primary Outcome Measures

Name	Time	Method
Change in amino-terminal pro-B-type natriuretic peptide (NT-proBNP)	7 months and 11 months

Secondary Outcome Measures

Name	Time	Method
≥5points improvement in the short Kansas City Cardiomyopathy Questionnaire score	7 months and 11 months
Reduction of left ventricular end-diastolic volume.	7 months and 11 months
Increase in 6-min walk test distance by ≥25 m	7 months and 11 months

Trial Locations

Locations (1)

Castle Hill Hospital; 🇬🇧 Hull, United Kingdom